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ABSTRACT
Objective: In intensive care, it is imperative to resolve
hypotensive episodes (HEs) in a timely manner to
minimise end-organ damage. Clinical practice guidelines
generally recommend initial treatment with ﬂuid
resuscitation followed by vasoactive agent
administration if patients remain hypotensive. However,
the impact of such interventions on patient outcomes
has not been clearly established. Hence, the objective of
this study was to investigate the relationship between
ﬂuid and vasoactive agent interventions and patient
outcomes, while highlighting the utility of electronic
medical records in clinical research.
Design: Retrospective cohort study.
Setting: Intensive care units (ICUs) at a large,
academic, tertiary medical center.
Participants: Patients in Multi-parameter Intelligent
Monitoring in Intensive Care II (a large electronic ICU
database) who experienced a single HE during their
ICU stay. 2332 patients had complete data.
Primary and secondary outcome measures: The
primary outcome of interest was inhospital mortality.
Secondary outcomes were ICU length of stay (LOS),
HE duration, Hypotension Severity Index (deﬁned as
the mean arterial pressure curve area below
60 mm Hg during the HE) and rise in serum
creatinine.
Results: Fluid resuscitation was associated with
signiﬁcantly shorter ICU LOS among ICU survivors
(p¼0.007). Vasoactive agent administration
signiﬁcantly decreased HE duration (p<0.001) and
Hypotension Severity Index (p¼0.002) but was
associated with increased inhospital mortality risk
(p<0.001), prolonged ICU LOS among ICU survivors
(p¼0.04) and rise in serum creatinine (p¼0.002) after
adjustment for confounders. Propensity score
analyses as well as sensitivity analyses in treatment-,
diagnosis- and ICU service-speciﬁc subpopulations
corroborated the relationship between vasoactive
agents and increased inhospital mortality.
Conclusions: An adverse relationship between
vasoactive agents and inhospital mortality was found
in patients with hypotension. This study has
implications for the care of critically ill patients with
hypotension and illustrates the utility of electronic
medical records in research when randomised
controlled trials are difﬁcult to conduct.
INTRODUCTION
Electronic medical records (EMRs) that
include detailed information on clinical care
afford researchers a unique opportunity to
evaluate both practice variation and the
impact of diagnostic and therapeutic deci-
sions on patient outcomes. When compiled
into clinical databases and used for research
purposes, they have potential advantages
compared with randomised controlled trials
(RCT). For example, clinical databases built
using EMRs require fewer resources to
mobilise for analysis, are capable of including
readily accessible information on large and
diverse patient populations and allow
research questions to be answered within
a shorter period of time. Their versatility also
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ARTICLE SUMMARY
Article focus
- To investigate the impact of ﬂuid resuscitation
and vasoactive therapy on patient outcomes in
critically ill patients who experienced a HE, using
an electronic database.
- To emphasise the utility of electronic medical
records in clinical research when prospective
randomised clinical trial results are absent.
Key messages
- Vasoactive agents were found to be correlated
with increased inhospital mortality risk, even
after propensity adjustment.
- Electronic medical records can help answer
clinical questions for which clinical trials are
challenging to conduct.
Strengths and limitations of this study
- The adverse relationship between vasoactive
agents and inhospital mortality was carefully
established using propensity score and sensi-
tivity analyses.
- The results of this paper are thought provoking
but inconclusive. It is possible that vasoactive
agents harm only a speciﬁc subset of the
critically ill.
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Open Access Researchmakes them a potential resource for policymakers, as
public and private healthcare payers increasingly rely on
clinical evidence to support practice guidelines and
coverage decisions. Another advantage associated with
EMRs is that they can be used to assess interventions in
real-life practice, whereas RCTs tend to focus on argu-
ably artiﬁcial clinical scenarios stemming from their
strict inclusion and exclusion criteria.
The Multi-parameter Intelligent Monitoring in Inten-
sive Care II (MIMIC-II) Database
1 is a clinical database
that provides detailed information about the care of
patients treated in intensive care units (ICUs). Critically
ill patients are an ideal population for clinical database
investigations because the clinical value of many treat-
ments and interventions they receive is unproven, and
high-quality data supporting or discouraging speciﬁc
practices is relatively sparse.
23We used MIMIC-II to
explore practice variation and health outcomes in criti-
cally ill patients admitted for or later developing hypo-
tension in an ICU. Hypotension is an important
condition to study in this setting because it is a risk factor
for hospital mortality and approaches to its treatment
vary widely (eg, colloids vs crystalloids for ﬂuid resusci-
tation
45 ). Moreover, many of the interventions used to
treat hypotension are associated with adverse events
including pulmonary oedema, heart failure and tissue
ischaemia.
6e9
METHODS
Study population
This study utilised the MIMIC-II Database (version 2.6),
a publicly available clinical database developed through
a collaboration among Massachusetts Institute of
Technology, Philips Healthcare and Beth Israel
Deaconess Medical Center.
1 MIMIC-II is a repository of
de-identiﬁed physiologic, laboratory, and survival
outcome data from approximately 25000 critically ill
adult patients cared for in the ICUs at Beth Israel
Deaconess Medical Center between 2001 and 2008.
These data include clinical variables such as patient age,
gender and chronic disease diagnoses as represented by
International Classiﬁcation of Diseases (ICD) codes;
laboratory data such as haematocrit, creatinine and
electrolytes; physiologic data such as blood pressure and
heart rate; markers of treatment intensity such as the
utilisation of invasive and non-invasive mechanical
ventilation, renal replacement therapy, central venous
lines, vasoactive agents and blood transfusion and
survival during and after the hospitalisation.
Patients in MIMIC-II who were cared for in medical
ICUs (MICU), surgical ICUs (SICU), coronary care units
(CCU) and cardiac surgery recovery units (CSRU) were
included in the study. In addition, patients were eligible
for inclusion in this study if they experienced a single
hypotensive episode (HE), and their code status was not
comfort measures only within 24 h before and after the
HE. Hypotension was deﬁned based on mean arterial
pressure (MAP) measurements obtained either by inva-
sive arterial catheters or non-invasive sphygmomanome-
ters. Both types of measurement were usually recorded
every 10e15 min in our cohort; although invasive arte-
rial catheters yield beat-by-beat blood pressure, we
utilised nurse-veriﬁed measurements that are still
recorded every 10e15 min. The beginning of an HE was
deﬁned as the time of the ﬁrst of two consecutive MAP
measurements #60 mm Hg, preceded by two consecu-
tive MAP values above 60 mm Hg. The end of an HE was
deﬁned as the time of the ﬁrst of two consecutive MAP
measurements >60 mm Hg, preceded by two consecu-
tive MAP values #60 mm Hg. A MAP threshold of
60 mm Hg was used in the study based on the ﬁnding
that autoregulation ceases and blood ﬂow becomes
pressure dependent below this level in various organs.
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Study variables and outcomes
The two primary independent variables of interest were
administration of intravenous ﬂuid and initiation or
increase in dosage of vasoactive agents during the HE.
Fluid resuscitation was deﬁned as at least one infusion of
either a bolus of isotonic crystalloid of at least 250 ml or
any volume of colloids. Vasoactive therapy was deﬁned as
an initiation or a dosage increase of dobutamine,
dopamine, epinephrine, norepinephrine, phenyleph-
rine or vasopressin during the HE. Not all patients
received ﬂuids or vasoactive agents during their HE.
The primary patient outcome was inhospital mortality,
while the secondary outcomes were ICU length of stay
(LOS) longer than 3 days, HE duration longer than 1 h,
Hypotension Severity Index (HSI), deﬁned as the MAP
curve area below 60 mm Hg during the HE and any
increase in serum creatinine level within 3 days following
the HE. Figure 1 illustrates how we calculated HSI for
each HE. HSI approximates the area between linearly
interpolated mean blood pressure measurements and
the 60 mm Hg and captures both HE duration and
magnitude of blood pressure in one metric. The unit of
HSI is mm Hg$min. As an outcome variable, HSI was
ﬁrst calculated as a continuous value and subsequently
dichotomised with a threshold of 150 mm Hg$min
(roughly the median HSI in the cohort). ICU LOS was
investigated in all patients, as well as only among the
patients who survived their ICU stay.
Control variables in this study included age, gender,
Simpliﬁed Acute Physiologic Score (SAPS) (a predictor
of mortality for critically ill patients), an Elixhauser
comorbidity score
11 calculated using the method
described by Van Walraven et al
12 (indicator of chronic
illness and secondary diagnoses), mean MAP in the 3 h
period immediately prior to the HE onset (measure of
haemodynamic status before the HE), total volume of
urine output in the 3-h period immediately prior to the
HE onset >200 ml (surrogate measure of organ perfu-
sion), last serum creatinine level prior to and within 24 h
of the HE onset (another surrogate measure of organ
perfusion) and service type (MICU, SICU, CCU or
CSRU). In addition, all propensity score models in this
study (to be discussed in the Statistical analysis section)
2 Lee J, Kothari R, Ladapo JA, et al. BMJ Open 2012;2:e000916. doi:10.1136/bmjopen-2012-000916
Treatment of hypotension in the critically illincluded the total volume of ﬂuids (normal saline and
lactated ringer) given to the patient between ICU
admission and the beginning of the HE.
Statistical analysis
The effects of hypotension treatment approaches on
patient outcomes were investigated after adjusting for
confounding variables using multivariate logistic regres-
sion. For each logistic regression model, the
HosmereLemeshow (H-L) goodness-of-ﬁt test
13 and
receiver operating characteristic curve analysis were
performed to evaluate the calibration and discrimina-
tion of the model, respectively. For all outcomes, p values
<0.05 were considered signiﬁcant.
In order to further address omitted variable bias in the
inhospital mortality analysis, a propensity score analysis
14
was employed to adjust for the likelihood of receiving
vasoactive therapy. A logistic regression model with all
control variables was built to estimate propensity scores
for receipt of vasoactive therapy, while remaining blind
to inhospital mortality. Propensity scores were then used
in a subsequent regression model as a regressor along
with the primary predictors (ﬂuids and vasoactive
agents), while the outcome variable was inhospital
mortality.
As a sensitivity analysis, inhospital mortality with and
without adjustment using propensity scores was analysed
after excluding patients who received neither ﬂuids nor
vasoactive agents during their HE. By focusing only on
treated patients, patients with a potentially clinically
unimportant HE were excluded. Similarly, inhospital
mortality with and without propensity score adjustment
was also investigated within patients who received either
only ﬂuids or both ﬂuids and vasoactive agents (in other
words, ﬂuid-resuscitated patients, who comprise a subset
of the treated patients). By excluding patients who
received only vasoactive agents and no ﬂuids during
their HE, this sensitivity analysis reduced the number of
patients whose clinical presentations were more severe.
In addition, differences across the four service types in
the underlying cause of hypotension, and hence in
hypotension treatment methods, were addressed by
conducting an ICU service-speciﬁc sensitivity analysis.
Speciﬁcally, a separate propensity score model was built
in each service type to investigate inhospital mortality.
We also performed subgroup analyses among patients
with sepsis and among patients with congestive heart
failure (CHF) based on ICD-9 codes. The rationale was
to address potential bias by indication. Separate logistic
regression models with propensity score adjustment were
constructed for these analyses.
All statistical analyses were performed using MATLAB
version R2010b (MathWorks, Natick, Massachusetts,
USA).
RESULTS
A total of 3163 patients in MIMIC-II met the inclusion
criteria. Of these patients, 63.3% and 81.6% developed
an HE within 24 and 48 h of ICU admission, respectively.
Table 1 summarises the demographic and clinical char-
acteristics of the patients in our cohort. The median HE
duration was 2 h. Most HEs (62.9%) were treated with
neither ﬂuids nor vasoactive agents, whereas 19.8% of
the patients were ﬂuid resuscitated. The incidence of
vasoactive agent use was 17.3% as monotherapy and
6.3% in combination with ﬂuids. The inhospital
mortality of the patient cohort was 12.9%, while the
median ICU LOS was 2.7 days. Of the 3163 patients, 732
and 354 were CHF and sepsis patients, respectively. Also,
1486 and 1677 patients were monitored using invasive
and non-invasive blood pressure measurement tech-
niques, respectively.
Table 2 summarises results for inhospital mortality
stratiﬁed by treatment. Of the 3163 patients, 2332 had
complete data and were included in multivariate anal-
yses. The largest contributor to missing data was serum
creatinine. While no signiﬁcant relationship was found
between ﬂuid resuscitation and inhospital mortality,
vasoactive therapy was associated with an increased
inhospital mortality risk in all (OR¼2.86, p<0.001),
treated (received either ﬂuids or vasoactive agents, or
both) (OR¼2.41, p¼0.02), and ﬂuid resuscitated
patients (received either only ﬂuids or both ﬂuids and
vasoactive agents) (OR¼2.30, p¼0.04). Among the
Figure 1 A pictorial illustration of
Hypotension Severity Index (HSI)
calculation. The greyed area in
mm Hg$min represents the HSI in
this particular case. Consecutive
mean blood pressure
measurements are linearly
interpolated, and the area below
60 mm Hg from the ﬁrst to last
measurement of the hypotensive
episodes (HE) is computed. HSI
has the advantage of harnessing
both magnitude of mean blood
pressure and HE duration.
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Treatment of hypotension in the critically illcontrol variables, older age, higher SAPS, higher Elix-
hauser, higher mean MAP prior to the HE, lower urine
output prior to the HE and MICU (in comparison to
SICU, CCU and CSRU) were signiﬁcantly associated with
higher inhospital mortality in the overall cohort. Among
the treated patients only, higher SAPS, higher Elix-
hauser, lower urine output prior to the HE and MICU
(in comparison to CSRU) were associated with higher
inhospital mortality. The multivariate analysis of ﬂuid-
resuscitated patients showed that higher SAPS, higher
Elixhauser, lower urine output prior to the HE and
MICU (in comparison to CCU and CSRU) were all
associated with an increased risk of death.
In estimating the propensity for vasoactive therapy in
the entire patient cohort, younger age, male gender,
higher SAPS, higher Elixhauser, lower urine output
prior to the HE and CSRU (in comparison to MICU)
were signiﬁcantly correlated with higher likelihood of
receiving vasoactive agents. In the treated patients,
higher SAPS, higher Elixhauser, higher serum creatinine
prior to the HE and CSRU (in comparison with MICU)
were signiﬁcant predictors of vasoactive therapy. Among
the patients who received ﬂuid resuscitation, higher
SAPS, higher serum creatinine prior to the HE and
CSRU (in comparison with MICU) were associated with
increased propensity. See table AI for detailed results of
the propensity score calculation models.
Table 3 summarises the relationship between vasoac-
tive therapy and inhospital mortality after propensity
score adjustment. Vasoactive therapy remained signiﬁ-
cantly associated with increased mortality, in all
(OR¼2.44, p<0.001), treated (OR¼2.21, p¼0.009) and
ﬂuid-resuscitated patients (OR¼1.03, p¼0.02). However,
in comparison with our results in table 2, the corre-
sponding vasoactive agent ORs for inhospital mortality
decreased, most substantially in patients who received
ﬂuid resuscitation (from 2.30 to 1.03).
The results from the ICU service-speciﬁc analysis are
tabulated in tables AII and AIII. After propensity
adjustment, the relationship between vasoactive agents
and higher inhospital mortality remained signiﬁcant in
all service types except CSRU. Fluid resuscitation was not
signiﬁcantly correlated with inhospital mortality in any
service type.
Our subgroup analyses yielded similar ﬁndings as the
main analyses. In the 732 patients with CHF, vasoactive
therapy remained signiﬁcantly correlated with inhospital
mortality after propensity score adjustment (OR¼2.00,
p¼0.004). Likewise, in the 354 sepsis patients, vasoactive
therapy was a signiﬁcant predictor of in-hospital mortality
with propensity score adjustment (OR¼2.84, p<0.001).
Table 4 provides the multivariate logistic regression
results for the secondary outcomes in all patients. We
found that ﬂuid resuscitation was signiﬁcantly associated
with shorter ICU LOS (all patients: OR¼0.71, p¼0.004;
ICU survivors: OR¼0.71, p¼0.007) and greater HSI
(OR¼1.26, p¼0.04). Vasoactive agent administration was
signiﬁcantly associated with longer ICU LOS among ICU
survivors (OR¼1.29, p¼0.04), shorter HE duration
(OR¼0.29, p<0.001), decreased HSI (OR¼0.72,
p¼0.002), and rise in serum creatinine (OR¼1.44,
p¼0.002).
Table 1 Demographic and clinical characteristics of the
study population (N¼3163)
Age* (years) 69.3 (56.9, 79.3)
Gender (male) 54.3%
Service type
MICU 33.2%
SICU 22.0%
CCU 15.8%
CSRU 29.0%
SAPS I* 15 (11, 19)
HE duration* (min) 120 (45, 120)
Hypotension treatment
No intervention 62.9%
Fluids only 13.5%
Vasoactive agents only 17.3%
Both ﬂuids and vasoactive agents 6.3%
Inhospital mortality 12.9%
ICU LOS* (days) 2.7 (1.6, 4.9)
Elixhauser comorbidities
Congestive heart failure 20.9%
Cardiac arrhythmias 21.0%
Valvular disease 8.6%
Pulmonary circulation disorders 2.4%
Peripheral vascular disorders 9.5%
Hypertension 30.9%
Paralysis 1.1%
Other neurological disorders 3.3%
Chronic pulmonary disease 16.4%
Diabetes, uncomplicated 21.2%
Diabetes, complicated 4.8%
Hypothyroidism 8.7%
Renal failure 5.1%
Liver disease 4.6%
Peptic ulcer disease excluding
bleeding
0.5%
AIDS 0.6%
Lymphoma 1.5%
Metastatic cancer 4.4%
Solid tumour without metastasis 10.8%
Rheumatoid arthritis/collagen
vascular disease
2.2%
Coagulopathy 6.1%
Obesity 1.6%
Weight loss 2.7%
Fluid and electrolyte disorders 24.3%
Blood loss anaemia 0%
Deﬁciency anaemias 11.9%
Alcohol abuse 3.7%
Drug abuse 1.8%
Psychoses 2.3%
Depression 4.1%
*Median (Q1,Q 3).
CCU, coronary care unit; CSRU, cardiac surgery recovery unit; HE,
hypotensive episode; LOS, length of stay; MICU, medical intensive
care unit; SAPS, Simpliﬁed Acute Physiology Score; SICU, surgical
intensive care unit.
4 Lee J, Kothari R, Ladapo JA, et al. BMJ Open 2012;2:e000916. doi:10.1136/bmjopen-2012-000916
Treatment of hypotension in the critically illDISCUSSION
Clinical databases built using EMRs such as MIMIC-II
represent an opportunity to study clinical areas where
practice variation exists or care standards have not been
established. In this study, we examined treatment of
hypotension in the ICU. The decision to administer
intravenous ﬂuids or vasoactive agents, and the volume
or dose chosen, largely depend on the clinician’s pref-
erences and practice patterns within an ICU, along with
process-related factors at the time of the hypotensive
event (eg, physician presence at the bedside, nurse-to-
patient ratio, etc).
15 Clinician decision-making, in the
absence of strong guidelines, is frequently driven by prior
experience, which is particularly prevalent in intensive
care where RCT evidence is relatively sparse.
16 17
This results in signiﬁcant care variability not explained by
patient or contextual factors but instead driven by indi-
vidual provider practice. Use of inotropes, for example,
has been described as both hospital and physician
dependent, being administered to as few as 5% or to as
many as 100% of patients undergoing elective cardiac
surgery.
18 19
In our retrospective analysis, we did not ﬁnd signiﬁ-
cant variation in the rate of ﬂuid administration, with
majority of the patients receiving between 250 and
500 ml/h. The limited variability in ﬂuid administration
volume may explain why we did not ﬁnd a relationship
between ﬂuid administration and inhospital mortality or
Table 2 Multivariate logistic regression results for inhospital mortality
All patients,
OR (95% CI)
Treated patients,
OR (95% CI)
Fluid-resuscitated patients,
OR (95% CI)
Fluid resuscitation 0.87 (0.61 to 1.26) 0.75 (0.40 to 1.40) NA
Use of vasoactive agents 2.86* (2.09 to 3.92) 2.41* (1.19 to 4.88) 2.30* (1.05 to 5.03)
Age (year) 1.01* (1.00 to 1.02) 1.01 (0.99 to 1.02) 1.02 (1.00 to 1.05)
Gender (male) 0.96 (0.72 to 1.27) 0.93 (0.59 to 1.47) 0.82 (0.40 to 1.67)
SAPS 1.14* (1.11 to 1.18) 1.17* (1.12 to 1.22) 1.18* (1.10 to 1.27)
Elixhauser 1.24* (1.14 to 1.36) 1.15* (1.01 to 1.32) 2.00* (1.26 to 3.17)
Mean MAP prior to HE (mm Hg) 1.02* (1.00 to 1.03) 1.02 (1.00 to 1.04) 1.02 (0.99 to 1.06)
Urine output prior to HE >200 ml 0.65* (0.49 to 0.87) 0.57* (0.35 to 0.91) 0.30* (0.13 to 0.68)
Creatinine prior to HE (mg/dl) 1.07 (0.96 to 1.19) 1.07 (0.90 to 1.28) 1.05 (0.75 to 1.49)
Service type
MICUy 111
SICU 0.62* (0.43 to 0.88) 0.62 (0.35 to 1.08) 0.37* (0.15 to 0.91)
CCU 0.63* (0.42 to 0.94) 0.61 (0.32 to 1.14) 0.25* (0.07 to 0.86)
CSRU 0.08* (0.05 to 0.14) 0.05* (0.02 to 0.11) 0.14* (0.05 to 0.41)
Number of subjects 2332 812 409
AUC 0.831 0.868 0.877
HosmereLemeshow p value 0.37 0.40 0.86
Each column represents a separate regression model for a speciﬁc patient cohort. Treated patients received either ﬂuids or vasoactive agents
or both. Fluid-resuscitated patients received either only ﬂuids or both ﬂuids and vasoactive agents.
*Statistically signiﬁcant.
yReference.
AUC, area under the receiver operating characteristic curve; CCU, coronary care unit; CSRU, cardiac surgery recovery unit; HE, hypotensive
episode; MAP, mean arterial pressure; MICU, medical intensive care unit; NA, not applicable; SAPS, Simpliﬁed Acute Physiology Score; SICU,
surgical intensive care unit.
Table 3 Vasoactive therapy propensity score analysis results for inhospital mortality
All patients,
OR (95% CI)
Treated patients,
OR (95% CI)
Fluid-resuscitated
patients, OR (95% CI)
Fluid resuscitation 0.97 (0.70 to 1.33) 0.87 (0.54 to 1.41) NA
Use of vasoactive agents 2.44* (1.85 to 3.20) 2.21* (1.22 to 4.01) 1.03* (1.00 to 1.05)
Propensity for vasoactive therapy 2.03 (0.83 to 5.00) 0.96 (0.28 to 3.24) 5.41* (1.12 to 26.26)
Number of subjects 2332 812 409
AUC 0.621 0.602 0.629
HosmereLemeshow p value 0.01 0.02 0.03
Each column represents a separate regression model for a speciﬁc patient cohort. Treated patients received either ﬂuids or vasoactive agents
or both. Fluid-resuscitated patients received either only ﬂuids or both ﬂuids and vasoactive agents.
*Statistically signiﬁcant.
AUC, area under the receiver operating characteristic curve; NA, not applicable.
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Treatment of hypotension in the critically illsome of our secondary outcomes. The administration of
vasoactive agents, however, was an independent
predictor of inhospital mortality, and this relationship
persisted in the propensity score analysis. To address the
issue of confounding by indication, multivariate logistic
regression and propensity score analyses were
performed in each service type as well as in subsets of
patients with CHF or sepsis. In all of these analyses
except in CSRU patients, vasoactive agent use remained
independently associated with inhospital mortality.
Other studies have also reported that vasoactive
therapy may be associated with higher mortality. Shahin
and colleagues
20 found that hospital mortality and renal
dysfunction were consistently lower in patients unex-
posed to inotropes, even when their 6-h physiologic
variables were lower than literature-recommended
targets. In patients with heart failure, a systematic review
of controlled trials of catecholaminergic agents
compared with placebo found no improvement in patient
outcomesdindeed, there was evidence of harm.
21 Using
data from the multi-centre trial of N-omega-monomethyl-
L-arginine (L-NMMA) in septic shock, Dunser et al
22
found that mean vasoactive agent load was associated with
higher 28-day mortality.
Catecholamines have a wide range of potential adverse
effects,
6 including excess vasoconstriction and impaired
microcirculation leading to impaired organ perfusion
and increased metabolic demands, including myocardial
oxygen requirement. Furthermore, catecholamine use
has been associated with reduced metabolic efﬁciency
by promoting fatty acid oxidation. Catecholamines
have also been associated with increased bacterial viru-
lence and bioﬁlm formation and altered immune
response.
62 32 4
Clinical guidelines for the management of sepsis
25 and
cardiogenic shock
26 recommend ﬂuid resuscitation and
vasopressor/inotropic support. However, they also state
that the recommendations are based on a low level of
evidence. Furthermore, in a review article regarding
cardiogenic shock, Reynolds and Hochman
27 have
suggested that the lowest possible doses should be
administered when vasopressor and inotropic agents are
used, due to a possible relationship between high doses
of vasoactive agents and worse survival outcomes.
28
Clinical databases built using EMRs may be ideal
resources for evaluating the impact of vasoactive agents
on outcomes. Randomised placebo-controlled clinical
trials for commonly used vasoactive agents are either
unavailable or lack sufﬁcient statistical power to evaluate
differences in important clinical outcomes.
25 Our study
was not able to address whether the observed increase in
hospital mortality was more likely to occur with some
vasoactive agents than others due to inadequate power.
De Backer et al
29 found no signiﬁcant difference in 28-
day mortality between patients who received dopamine
as ﬁrst-line vasopressor therapy and those who received
norepinephrine, although dopamine use was associated
with signiﬁcantly more arrhythmias. In our cohort, there
were 76 and 171 patients who received only dopamine
and norepinephrine, respectively. The unadjusted
inhospital mortality rates in the dopamine and norepi-
nephrine groups were 39.5% and 32.8%, respectively.
It is important to note that, despite our use of
propensity scores, residual confounding remains
a concern. We attempted to address this by repeating our
analyses in patient subsets, but we may not have fully
adjusted for severity of illness. Little data elsewhere exist
that examine the impact of vasoactive agents on end-
organ preservation. This area may be a promising one
for clinical trials.
There are a few limitations associated with the present
study. First, potential bias stemming from missing data
abounds. Of the 3163 patients who met the inclusion
criteria, 2332 had complete data and were analysed.
Second, the duration and dosage of vasoactive therapy
during the HE were not investigated. The analysis was
restricted to the identiﬁed HEs; the use of vasoactive
agents throughout the ICU stay outside the HE was not
evaluated. Third, although we included the total amount
of ﬂuids given to the patient prior to the HE in the
propensity score models, an assessment of ﬂuid respon-
siveness was not included in the models. Traditional
static measures such as central venous pressure were not
consistently obtained among the patients and have been
shown to be poorly predictive of ﬂuid responsiveness.
30
Dynamic measures have not been sufﬁciently stand-
ardised and validated across critically ill patients, espe-
cially those who are spontaneously breathing, those who
are mechanically ventilated but not deeply sedated or
those who have cardiac arrhythmias. We made the
assumption that vasoactive agents were initiated or their
dose increased after clinician assessment that the patient
will not beneﬁt from additional ﬂuid administration.
Alternative interpretations of our ﬁndings are
possible. It may be that the adverse relationship between
vasoactive agents and survival actually comprises
a combination of incremental beneﬁts in a subset of
patients that are outweighed by incremental harms in
another subset. The threshold blood pressure below
which end-organ damage ensues likely differs among
patients and perhaps even within the same patient in
different clinical contexts. The clinical challenge is to
predict the lowest blood pressure threshold for which no
treatment is required. The concept of permissive hypo-
tension has been introduced in the neonatal intensive
care literature based on ﬁndings of similar outcomes
between normotensive and hypotensive low birth weight
infants with signs of good perfusion.
31 Permissive hypo-
tension would be challenging to investigate prospec-
tively; however, analyses with robust electronic medical
records may hold the key to unravelling this conundrum.
Our study is a ﬁrst step in examining management of
hypotension in the ICU, and it suggests potential areas
of investigation and standardisation of processes of care.
The frequency of vasoactive agent use in the ICU may
have engendered a perception of safety. Titration of
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using a ﬁxed blood pressure target is straightforward to
apply at the bedside and likely perceived as rewarding to
the staff. Personalised guidelines that are patient and
context speciﬁc may be more beneﬁcial, particularly
when treatment is associated with signiﬁcant harm.
Robust customisation of hypotensive thresholds may be
best achieved by utilising extensive real-time modelling
of physiologic variables on a patient-by-patient basis.
Prospectively, prediction of outcomes with vasoactive
therapy may be sought with the help of growing clinical
databases to create treatment algorithms.
In a previous study, Celi et al
32 introduced a method of
designing decision support tools based on a hospital’s
own clinical database as an alternative to expert systems
derived from large, multi-centre, interventional or obser-
vational studies. Using the term ‘Collective Experience’ to
refer to the aggregation of patient care data from clini-
cians working in a single institution, they proposed
developing guideline models from a more homogeneous
group of patients because of the trade-off between
generalisability and accuracy. The utility of a local EMR in
clinical decision support when the existing literature lacks
relevant evidence was also discussed by Frankovich et al.
33
Clinical guidelines developed by a single institution may
provide diagnostic assistance, treatment guidance and
prognostic capabilities that are more personalised and
appropriate for an institution’s patient population. The
vision is a data-fuelled learning system that aggregates and
analyzes day-to-day experimentations, where new knowl-
edge is constantly extracted and propagated for quality
improvement and where practice is driven by outcomes
and less so by individual clinician knowledge base and
experience and the local medical culture.
CONCLUSIONS
Using an EMR, we found that patients who were exposed
to vasoactive therapy during HEs were more likely to die,
a ﬁnding consistent with other studies in sepsis, cardiac
surgery and heart failure. Clinical databases such as
MIMIC-II can complement knowledge gained from
conventional comparative effectiveness research
methods and provide important insights about routine
patient care.
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Table AI The relationships between demographic/clinical variables and the propensity for receipt of vasoactive therapy
All patients, OR (95% CI)
Treated patients,
OR (95% CI)
Fluid-resuscitated
patients, OR (95% CI)
Age (year) 0.99* (0.99 to 1.00) 0.99 (0.98 to 1.01) 0.99 (0.98 to 1.01)
Gender (male) 1.55* (1.25 to 1.92) 1.21 (0.87 to 1.67) 1.34 (0.83 to 2.18)
SAPS 1.12* (1.09 to 1.14) 1.09* (1.06 to 1.13) 1.12* (1.07 to 1.17)
Elixhauser 1.08* (1.01 to 1.17) 1.30* (1.03 to 1.64) NA
Mean MAP prior to HE
(mm Hg)
1.01 (0.99 to 1.02) 1.01 (0.99 to 1.03) 1.00 (0.98 to 1.03)
Urine output prior to HE
>200 ml
0.71* (0.57 to 0.88) 0.85 (0.61 to 1.18) 0.98 (0.60 to 1.59)
Creatinine prior to HE (mg/dl) 1.01 (0.92 to 1.11) 1.28* (1.07 to 1.52) 1.29* (1.02 to 1.64)
Total volume of ﬂuids given
prior to HE (L)
1.01 (0.97 to 1.05) 1.01 (0.96 to 1.07) 0.97 (0.89 to 1.05)
Service type
MICUy 11 1
SICU 0.74 (0.53 to 1.03) 0.95 (0.60 to 1.50) 1.28 (0.64 to 2.56)
CCU 1.37 (0.97 to 1.94) 1.68 (1.00 to 2.84) 1.41 (0.59 to 3.37)
CSRU 2.06* (1.55 to 2.75) 2.84* (1.87 to 4.32) 3.56* (1.91 to 6.62)
Number of subjects 2332 812 409
AUC 0.726 0.703 0.729
HosmereLemeshow p value 0.03 0.17 0.16
Each column represents a separate propensity score model for a speciﬁc patient cohort. Treated patients received either ﬂuids or vasoactive
agents or both. Fluid-resuscitated patients received either only ﬂuids or both ﬂuids and vasoactive agents.
*Statistically signiﬁcant.
yReference.
AUC, area under the receiver operating characteristic curve; CCU, coronary care unit; CSRU, cardiac surgery recovery unit; HE, hypotensive
episode; MAP, mean arterial pressure; MICU, medical intensive care unit; NA, not applicable (due to a lack of signiﬁcant relationship with receipt
of vasoactive therapy); SAPS, Simpliﬁed Acute Physiology Score; SICU, surgical intensive care unit.
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Treatment of hypotension in the critically illTable AII The relationships between demographic/clinical variables and the propensity for receipt of vasoactive therapy in
different service types
MICU, OR (95% CI) SICU, OR (95% CI) CCU, OR (95% CI) CSRU, OR (95% CI)
Age (year) 0.99 (0.98 to 1.00) 0.99 (0.98 to 1.01) 0.99 (0.96 to 1.01) 1.00 (0.99 to 1.01)
Gender (male) 1.86* (1.20 to 2.87) 1.45 (0.84 to 2.49) 1.50 (0.84 to 2.69) 1.60* (1.14 to 2.24)
SAPS 1.16* (1.11 to 1.21) 1.15* (1.09 to 1.21) 1.15* (1.09 to 1.21) 1.04* (1.00 to 1.09)
Elixhauser 1.04 (0.91 to 1.20) 1.09 (0.93 to 1.29) 1.23* (1.02 to 1.49) 1.05 (0.93 to 1.18)
Mean MAP prior to HE
(mm Hg)
1.00 (0.98 to 1.03) 1.01 (0.99 to 1.04) 1.03 (1.00 to 1.06) 0.99 (0.97 to 1.01)
Urine output prior to HE
>200 ml
0.57* (0.36 to 0.92) 0.50* (0.29 to 0.86) 1.29 (0.74 to 2.25) 0.72* (0.52 to 1.00)
Creatinine prior to HE (mg/dl) 1.10 (0.96 to 1.27) 1.10 (0.90 to 1.35) 1.09 (0.88 to 1.36) 0.57* (0.40 to 0.79)
Total volume of ﬂuids given
prior to HE (L)
1.03 (0.95 to 1.13) 1.02 (0.92 to 1.14) 0.99 (0.89 to 1.11) 1.00 (0.94 to 1.07)
Number of subjects 692 535 379 726
AUC 0.751 0.748 0.740 0.603
HosmereLemeshow p value 0.71 0.01 0.93 0.33
Each column represents a separate propensity score model for a speciﬁc service type.
*Statistically signiﬁcant.
AUC, area under the receiver operating characteristic curve; CCU, coronary care unit; CSRU, cardiac surgery recovery unit; HE, hypotensive
episode; MAP, mean arterial pressure; MICU, medical intensive care unit; SAPS, Simpliﬁed Acute Physiology Score; SICU, surgical intensive
care unit.
Table AIII The vasoactive therapy propensity score analysis results for inhospital mortality in different service types
MICU, OR (95% CI) SICU, OR (95% CI) CCU, OR (95% CI)
CSRU, OR
(95% CI)
Fluid resuscitation 1.02 (0.62 to 1.69) 0.64 (0.30 to 1.37) 0.52 (0.17 to 1.61) 2.14 (0.84 to 5.46)
Use of vasoactive agents 2.90* (1.82 to 4.61) 4.53* (2.46 to 8.34) 3.20* (1.58 to 6.48) 0.71 (0.27 to 1.89)
Propensity for vasoactive
therapy
70.20*
(17.86 to 275.94)
147.57*
(19.39 to 1122.96)
186.24*
(24.41 to 1420.79)
0.00*
(0.00 to 0.43)
Number of subjects 692 535 379 726
AUC 0.729 0.751 0.791 0.645
HosmereLemeshow p value 0.29 0.02 0.33 0.37
Each column represents a separate regression model for a speciﬁc service type. The propensity for vasoactive therapy was calculated by the
models shown in the table above.
*Statistically signiﬁcant.
AUC, area under the receiver operating characteristic curve; CCU, coronary care unit; CSRU, cardiac surgery recovery unit; MICU, medical
intensive care unit; SICU, surgical intensive care unit.
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